Skip to main content

Table 3 The specific baseline clinicopathological characteristics of 156 Her2-positive breast cancer samples

From: Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer

 156 Her2-positive breast cancer samples
Age
 < 60 years75
 ≥ 60 years81
Stage
 I18
 II92
 III41
 IV3
 Unknown2
Pathologic T stage
 T1–2133
 T3–423
Pathologic N stage
 N0–1119
 N2–335
 Unknown2
Pathologic M stage
 M0132
 M13
 Unknown21
Survival time
 ≤ 1 year37
 1 year ≤ 3 years62
 3 years ≤ 5 years31
 > 5 years26